Progression of coronary artery atherosclerosis after acute myocardial infarction: An angiographic study

Journal of Invasive Cardiology

Volumn 22, Issue 5, 2010, Pages 209-215

  Hawranek, Michal ^a   Gasior, Mariusz ^a   Gierlotka, Marek ^a   Wilczek, Krzysztof ^a   Lekston, Andrzej ^a   Szygula Jurkiewicz, Bozena ^a   Spatuszko, Artur ^a   Polonski, Lech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

acute myocardial infarction; atherosclerosis progression; atrial septal defect; Occlutech; patent foramen ovale

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; FAMILY HISTORY; FEMALE; HEART INFARCTION; HEART PERFUSION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; RISK ASSESSMENT; SMOKING; CORONARY ARTERY BLOOD FLOW; FOLLOW UP; HEART STROKE VOLUME; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; STROKE VOLUME;

EID: 77955877471     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-1075.
2. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 1992;268:1429-1433.
3. Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial qunatative coronary angiography and coronary events. Am Heart J 2000;139:993-999.
4. Fuster V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994;90:2126-2146.
5. Libby P. Molecular bases of acute coronary syndromes. Circulation 1995;91:2844-2850.
6. Guazzi MD, Bussotti M, Grancini L, et al. Evidence of multifocal activity of coronary disease in patients with acute myocardial infarction. Circulation 1997;96:1145-1151.
7. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-922.
8. Riofoul G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three vessel intravascular ultrasound study. Circulation 2002;106:804-808.
9. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study. J Am Coll Cardiol 2001;37:1284-1288.
10. Gasior M, Gierlotka M, Lekston A, et al. Comparison of outcomes of direct stenting versus stenting after balloon predilatation in patients with acute myocardial infarction (DIRAMI). Am J Cardiol 2007;100:798-805.
11. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-936.
12. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
13. Waters D, Lesperance J, Craven TE, et al. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials. Circulation 1993;87(Suppl 2):38-47.
14. Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflenbeul W, and the INTACT Study Group. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Circulation 1992;86;828-838.
15. Liuzzo G, Biasucci LM, Gallimore JR, The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
16. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
17. Erratum, N Engl J Med 1997;337:356.
18. Kausik KR, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-1433.
19. Falk E. Pathogensis of atherosclerosis. J Am Coll Cardiol 2006;47;7-12.
20. Gertz SD, Roberts WC. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques. Am J Cardiol 1990;66:1368-1372.
21. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985;313:1315-1322.
22. Waters D, Lesperance J, Francetich M, et al. A controlled cIinical trial to assess the elIect of a calcium channel blocker on the progression of coronary atheroscIerosis. Circulation 1990;82:1940-1953.
23. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-286.
24. Blankenhorn DH, Azen SP, Kramsch DM, et al. The MARS Research Group: Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
25. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
26. Hasdai D, Garratt KN, Grill DE, Lerman A, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997;336:755-761.
27. Waters D, Lesperance J, Gladstone P, et al. for the CCAIT Study Group: Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996;94:614-621.
28. Jukema JW, Bruschke AVG, van Boven AJ, et al. on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
29. Meisel SR, Shapiro H, Radnay J, et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: Possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol 1998;31:120-125.
30. Most AS, Ruocco NA Jr, Gewirtz H. Effect of a reductuion in blood viscosity on maximal myocardial oxygen delivery distal to a moderate coronary stenosis. Circulation 1986;74:1085-1092.
31. Jaski BE, Cohen JD, Trausch J, et al. Outcome of urgent percutaneous transluminal coronary angioplasty in acute myocardial infarction: Comparison of single-vessel versus multivessel coronary artery disease. Am Heart J 1992;124:1427-1433.
32. Kereiakes DJ, Topol EJ, George BS. Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. J Am Coll Cardiol 1991;17:304-312.
33. Herd JA, Ballantyne CM, Farmer JA, et al. for the LCAS Investigators: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-286.
34. MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
35. Waters D, Higginson L, Gladstone P, et al; for the CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
36. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995;92:2419-2425.
37. Nissen SE, Nichols SJ, Sipahi I, et al. for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA 2006;295:1556-1565.
38. Nissen SE, Tuzcu EM, Schoenhagen P, et al. for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:1071-1080.
39. Hanratty CG, Koyama Y, Rasmussen HH, et al. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: Implications for immediate umltivessel revasulariztion. J Am Coll Cardiol 2002;40:911-916.
40. Glagov S, Weisenberg E, Zarins CHK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375.